The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05047185
Recruitment Status : Active, not recruiting
First Posted : September 17, 2021
Last Update Posted : February 21, 2024
Information provided by (Responsible Party):
Pharvaris Netherlands B.V.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : October 2, 2023
Estimated Study Completion Date : December 2026